These data suggest that although healthy tissues are enriched in different ILC subsets, when perturbed with tumor, anti-PD-1 treatment can expand Tbet+NK1.1− ILC in different tumor types and enhance production of IFNγ by this subset. This evidence concerns the gene PDCD1 and neoplasm.